CredoScientia - Bibliothèque

Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report.

Hepatocellular carcinoma (HCC) recurrence, which encompasses both true recurrence resulting from cancer spread and de novo tumors developing within the same cancer-prone liver, presents a complication…

Thérapies de Conversion

Chen, J., Liao, X., Wu, Y., Ou, S., Qin, W., Yang, C., Tan, Y., Lao, Q., Peng, M., Peng, T., & Ye, X. (2023). Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report.. Pharmgenomics Pers Med, 16, 949-958. https://doi.org/10.2147/PGPM.S426791

01/01/2023 Lire →

Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simult

BACKGROUND: Advanced hepatocellular carcinoma (HCC) shows poor prognosis. Combined hepatic artery infusion chemotherapy (HAIC) and lenvatinib and PD-1 antibody therapy show promising effects in treati…

Thérapies de Conversion

Luo, X., Chang, R. Z., Kuang, D., Yuan, M., Li, G. X., Zhang, B., Wang, Y. J., Zhang, W. G., & Ding, Z. Y. (2023). Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simult. Front Immunol, 14, 1285296. https://doi.org/10.3389/fimmu.2023.1285296

01/01/2023 Lire →

Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review.

Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment…

Thérapies de Conversion

Zhang, Z., Wang, X., Li, H., Sun, H., Chen, J., & Lin, H. (2023). Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review.. Front Immunol, 14, 1230261. https://doi.org/10.3389/fimmu.2023.1230261

01/01/2023 Lire →

Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.

BACKGROUND: Hepatocellular carcinoma (HCC) with a dismal prognosis is the second most deadly malignancy globally. Surgery is believed to be a curative approach. Nevertheless, there is still a consider…

Thérapies de Conversion

Wei, Y. G., Su, H., Lv, Z. L., Liao, X. W., Zeng, Z. M., Jia, Y. X., Huang, H. S., Shen, X. Q., Zhu, G. Z., Han, C. Y., Ye, X. P., & Peng, T. (2023). Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.. Front Oncol, 13, 1165538. https://doi.org/10.3389/fonc.2023.1165538

01/01/2023 Lire →

Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory V600E-mutated Colorectal Cancer With Para-aortic Lymph Node Metastases.

BACKGROUND/AIM: Mutant BRAF V600E colorectal cancer accounts for 5% of metastatic colorectal cancers, and it has a poor response to systemic chemotherapy and a poor prognosis. However, combination tre…

Thérapies de Conversion

Kawata, A., Miyamoto, Y., Fukubayashi, K., Horio, T., Miyamoto, H., Ogawa, K., Ouchi, M., Tanaka, Y., & Baba, H. (2023). Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory V600E-mutated Colorectal Cancer With Para-aortic Lymph Node Metastases.. In Vivo, 37(4), 1797-1801. https://doi.org/10.21873/invivo.13269

01/01/2023 Lire →

The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.

PURPOSE: To explore the safety and efficacy of lenvatinib in combination with trans-arterial chemoembolization (TACE) and programmed death receptor 1 (PD-1) antibody in the treatment of unresectable r…

Thérapies de Conversion

Mu, C., Shen, J., Zhu, X., Peng, W., Zhang, X., & Wen, T. (2023). The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.. Front Oncol, 13, 1096955. https://doi.org/10.3389/fonc.2023.1096955

01/01/2023 Lire →

Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two

Hepatocellular carcinoma (HCC) is often diagnosed at an unresectable stage without opportunities for curative therapy. Future liver remnant (FLR) insufficiency limits the range of patients who can und…

Thérapies de Conversion

Ning, C., Liu, G., Zhang, J., Yang, X., Xu, Y., & Zhao, H. (2023). Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two. Front Immunol, 14, 1159885. https://doi.org/10.3389/fimmu.2023.1159885

01/01/2023 Lire →

The role of F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

PURPOSE: To investigate the diagnostic value of F-fluorodeoxyglucose positron emission tomography (F-FDG PET), as an imaging biomarker, for predicting pathological response and prognosis of unresectab…

Thérapies de Conversion

Wang, G., Zhang, W., Luan, X., Wang, Z., Liu, J., Xu, X., Zhang, J., Xu, B., Lu, S., Wang, R., & Ma, G. (2023). The role of F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.. Front Immunol, 14, 1151967. https://doi.org/10.3389/fimmu.2023.1151967

01/01/2023 Lire →

Pathologic complete response to chemoimmunotherapy of an advanced gastric cancer patient with high PD-L1 expression, dMMR, and unique gut microbiota composition: A case report.

BACKGROUND: Advanced gastric cancer (AGC) is a malignant disease with limited therapeutic options and a poor prognosis. Recently, immune checkpoint inhibitors (ICIs), represented by inhibitors of prog…

Thérapies de Conversion

Jiang, H., Wang, J., & Deng, W. (2023). Pathologic complete response to chemoimmunotherapy of an advanced gastric cancer patient with high PD-L1 expression, dMMR, and unique gut microbiota composition: A case report.. Front Oncol, 13, 1150931. https://doi.org/10.3389/fonc.2023.1150931

01/01/2023 Lire →

Case report: A ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib.

BACKGROUND: Gallbladder cancer (GBC) is highly lethal and resistant to most chemotherapeutic drugs. GBC was reported to carry multiple genetic mutations such as TP53, K-RAS, and ERBB2/3. Here, we unex…

Thérapies de Conversion

Yang, J. X., Jia, Z. Y., Liu, F. T., Wu, W. G., Li, X. C., Zou, L., Li, H. F., Zhang, F., Bao, R. F., Peng, S. Y., Lau, W. Y., Liu, Y., Li, M. L., & Liu, Y. B. (2023). Case report: A ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib.. Front Oncol, 13, 1078388. https://doi.org/10.3389/fonc.2023.1078388

01/01/2023 Lire →

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.

PURPOSE: To evaluate the outcomes and prognostic factors for patients using conversion therapy with lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus programmed cell death …

Thérapies de Conversion

Li, X., Chen, J., Wang, X., Bai, T., Lu, S., Wei, T., Tang, Z., Huang, C., Zhang, B., Liu, B., Li, L., & Wu, F. (2023). Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.. Front Oncol, 13, 1110689. https://doi.org/10.3389/fonc.2023.1110689

01/01/2023 Lire →

Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report.

Situs inversus totalis (SIT) is a rare congenital condition in which abdominal and thoracic organs are transposed from normal positions. Two-stage hepatectomy (TSH) combined with translational therapy…

Thérapies de Conversion

Wu, Y., Ou, S., Liao, X., Han, C., Yang, C., Qin, W., Tan, Y., Lao, Q., Peng, T., & Ye, X. (2023). Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report.. Pharmgenomics Pers Med, 16, 111-120. https://doi.org/10.2147/PGPM.S376596

01/01/2023 Lire →